Style | Citing Format |
---|---|
MLA | Pourfarzam S, et al.. "Distinct Inflammatory Profiles in Mustard Lung: A Study of Sulfur Mustard-Exposed Patients With Serious Pulmonary Complications." International Immunopharmacology, vol. 146, no. , 2025, pp. -. |
APA | Pourfarzam S, Ardestani SK, Jamali T, Ghazanfari H, Naghizadeh MM, Faghihzadeh S, Yaraee R, Ghazanfari Z, Ghazanfari T (2025). Distinct Inflammatory Profiles in Mustard Lung: A Study of Sulfur Mustard-Exposed Patients With Serious Pulmonary Complications. International Immunopharmacology, 146(), -. |
Chicago | Pourfarzam S, Ardestani SK, Jamali T, Ghazanfari H, Naghizadeh MM, Faghihzadeh S, Yaraee R, Ghazanfari Z, Ghazanfari T. "Distinct Inflammatory Profiles in Mustard Lung: A Study of Sulfur Mustard-Exposed Patients With Serious Pulmonary Complications." International Immunopharmacology 146, no. (2025): -. |
Harvard | Pourfarzam S et al. (2025) 'Distinct Inflammatory Profiles in Mustard Lung: A Study of Sulfur Mustard-Exposed Patients With Serious Pulmonary Complications', International Immunopharmacology, 146(), pp. -. |
Vancouver | Pourfarzam S, Ardestani SK, Jamali T, Ghazanfari H, Naghizadeh MM, Faghihzadeh S, et al.. Distinct Inflammatory Profiles in Mustard Lung: A Study of Sulfur Mustard-Exposed Patients With Serious Pulmonary Complications. International Immunopharmacology. 2025;146():-. |
BibTex | @article{ author = {Pourfarzam S and Ardestani SK and Jamali T and Ghazanfari H and Naghizadeh MM and Faghihzadeh S and Yaraee R and Ghazanfari Z and Ghazanfari T}, title = {Distinct Inflammatory Profiles in Mustard Lung: A Study of Sulfur Mustard-Exposed Patients With Serious Pulmonary Complications}, journal = {International Immunopharmacology}, volume = {146}, number = {}, pages = {-}, year = {2025} } |
RIS | TY - JOUR AU - Pourfarzam S AU - Ardestani SK AU - Jamali T AU - Ghazanfari H AU - Naghizadeh MM AU - Faghihzadeh S AU - Yaraee R AU - Ghazanfari Z AU - Ghazanfari T TI - Distinct Inflammatory Profiles in Mustard Lung: A Study of Sulfur Mustard-Exposed Patients With Serious Pulmonary Complications JO - International Immunopharmacology VL - 146 IS - SP - EP - PY - 2025 ER - |